CasImg
瑞他霉素盐酸盐
产品纠错
CAS号:857402-63-2 | 英文名称:Retaspimycin Hydrochloride
分子式 C31H47N3O8.ClH
分子量 626
EINECS号 200-258-5
MDL
Smiles
InChIKey
乙二醇化学百科
基本信息
中文名称 瑞他霉素盐酸盐
英文名称 Retaspimycin Hydrochloride
CAS号 857402-63-2
分子式 C31H47N3O8.ClH
分子量 626.186
EINECS号 200-258-5
物化性质
溶解度 ≥26.1 mg/mL,溶于 DMSO,温和加热;不溶于水; ≥100 mg/mL,乙醇溶液,超声波
形态 固体
颜色 米白色至粉红色
安全信息
生产及用途
Retaspimycin Hydrochloride是有效的 Hsp90 抑制剂,EC50 为119 nM。

HSP90

119 nM (EC 50 )

GRP94

119 nM (EC 50 )

Retaspimycin (IPI-504) is a novel and highly soluble analog of 17AAG, an inhibitor of Hsp90. Retaspimycin can abrogate both the unfolded protein response element (UPRE) and ERSE-driven luciferase activity in non-treated U266 and MM.1s cells as well as in Tunicamycin (Tm)-treated cells. The IC 50 s for the inhibition of reporter gene activity by Retaspimycin are 196±56 nM in U266 and 472±177 nM in MM.1s for UPRE-luc activity and 213±140 nM for the ERSE-driven activity in MM.1s cells. Retaspimycin treatment leads to a dose-dependent decrease of p50ATF6 with EC 50 of 237 nM, consistent with the reporter-gene assay. The level of sXBP1 is decreased in the presence of Retaspimycin with an apparent EC 50 between 300 nM and 1 μM. Incubation of Retaspimycin (IPI-504) potently suppresses both Akt and MAPKs phosphorylation in both sensitive and Trastuzumab-resistant cells. Total levels of Akt decreased in all 4 cell lines (BT474, SKBR-3, HCC1569, and HCC1569) in a dose-dependent manner. However, levels of total MAPKs are not significantly altered with Retaspimycin treatment.

Retaspimycin (IPI-504) and Trastuzumab independently induce tumor regression of Trastuzumab-sensitive BT474 cell-derived xenografts. Xenografts derived from BT474R cells continue to grow in the presence of Trastuzumab but are still sensitive to Retaspimycin. When used in combination, Retaspimycin and Trastuzumab add only marginal benefits to Retaspimycin monotherapy. Retaspimycin (100 mg/kg) as a single agent is more efficacious than Trastuzumab in inhibiting tumor growth in HCC1569 xenografts. The combination is not significantly superior to Retaspimycin used as a single agent.

上下游产品
上游产品共计:0个
下游产品共计:0个
产品供应商

首页 |  CAS目录 |  产品目录 |  企业会员 |  关于我们 |  法律声明 |  注册协议

Copyright © 冀ICP备2024096099号